Regulating Pharmaceutical Prices in India Policy Design, Implementation and Compliance /

This book presents an extensive study on the effectiveness of recent regulations on pharmaceutical prices in India, exploring the weaknesses in the design and implementation of pharmaceutical price controls and investigating what can be done to fix the broken system. In addition, it examines the ext...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας: Bhaskarabhatla, Ajay (Συγγραφέας, http://id.loc.gov/vocabulary/relators/aut)
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2018.
Έκδοση:1st ed. 2018.
Σειρά:India Studies in Business and Economics,
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 04395nam a2200565 4500
001 978-3-319-93393-1
003 DE-He213
005 20191029021048.0
007 cr nn 008mamaa
008 180801s2018 gw | s |||| 0|eng d
020 |a 9783319933931  |9 978-3-319-93393-1 
024 7 |a 10.1007/978-3-319-93393-1  |2 doi 
040 |d GrThAP 
050 4 |a RA410-410.9 
072 7 |a KCQ  |2 bicssc 
072 7 |a BUS069000  |2 bisacsh 
072 7 |a KCVJ  |2 thema 
082 0 4 |a 338.473621  |2 23 
100 1 |a Bhaskarabhatla, Ajay.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
245 1 0 |a Regulating Pharmaceutical Prices in India  |h [electronic resource] :  |b Policy Design, Implementation and Compliance /  |c by Ajay Bhaskarabhatla. 
250 |a 1st ed. 2018. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2018. 
300 |a IX, 306 p. 24 illus., 18 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a India Studies in Business and Economics,  |x 2198-0012 
505 0 |a Introduction -- Part I. Historical Context and the Motivation for Regulation -- Brief History of Regulating Pharmaceutical Prices -- Is the 2013 Price Control Regulation Necessary? -- Part II. The Design of the 2013 DPCO Regulation -- The Proposed Design to Fix Ceiling Prices Under 2013 DPCO -- Challenges with Fixing the Ceiling Price Under the 2013 DPCO -- Part III. The Impact of the 2013 DPCO -- How Effective Are the 2013 DPCO Regulations? -- Firm Strategies to Mitigate the Impact of Price Control Regulation -- Part IV. Enforcement and Compliance -- Enforcement and Compliance with Price Ceilings on Essential Medicines -- Conclusion. . 
520 |a This book presents an extensive study on the effectiveness of recent regulations on pharmaceutical prices in India, exploring the weaknesses in the design and implementation of pharmaceutical price controls and investigating what can be done to fix the broken system. In addition, it examines the extent to which essential medicines are actually made affordable by price controls. The book argues that companies make the pharmaceutical price control regime largely ineffective by coordinating to increase pre-regulation prices; by diversifying horizontally away from the regulated markets and increasing prices in the unregulated markets; by manipulating trade margins; and by refusing to comply with the regulation because the penalties remains negligible. The book draws on extensive empirical research involving India's 2013 Drug Price Control Order and widely-used medicines such as paracetamol and metformin to illustrate how firms have weakened regulation. It argues that the regulatory regime can be strengthened by using systematic analysis of product- and region-level data in the Indian pharmaceutical industry, and by screening for the strategies that firms currently employ to circumvent regulation. In closing, it discusses recent efforts to strengthen the implementation of price controls in India and expanding the scope of price controls to medical devices. 
650 0 |a Health economics. 
650 0 |a Globalization. 
650 0 |a Markets. 
650 0 |a Pharmacy management. 
650 0 |a Economic policy. 
650 0 |a Development economics. 
650 1 4 |a Health Economics.  |0 http://scigraph.springernature.com/things/product-market-codes/W35000 
650 2 4 |a Emerging Markets/Globalization.  |0 http://scigraph.springernature.com/things/product-market-codes/525010 
650 2 4 |a Pharmacoeconomics and Health Outcomes.  |0 http://scigraph.springernature.com/things/product-market-codes/H69020 
650 2 4 |a Economic Policy.  |0 http://scigraph.springernature.com/things/product-market-codes/W34010 
650 2 4 |a Development Economics.  |0 http://scigraph.springernature.com/things/product-market-codes/W42000 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783319933924 
776 0 8 |i Printed edition:  |z 9783319933948 
776 0 8 |i Printed edition:  |z 9783030066529 
830 0 |a India Studies in Business and Economics,  |x 2198-0012 
856 4 0 |u https://doi.org/10.1007/978-3-319-93393-1  |z Full Text via HEAL-Link 
912 |a ZDB-2-ECF 
950 |a Economics and Finance (Springer-41170)